Key result
Novel HDAC inhibitor HDI-1 attenuates aortic plaque progression by selectively targeting HDAC2.
Answers are grounded in this paper and cite their sources.
HDI-1, a novel selective HDAC2 inhibitor, is being investigated for its potential to suppress lipid accumulation and ameliorate atherosclerosis in preclinical models.
Histone deacetylase 2 (HDAC2) critically regulates macrophage inflammatory responses and lipid metabolism, yet its potential as a therapeutic target in atherosclerosis (AS) remains to be fully established. This study investigates the therapeutic effects and molecular mechanisms of HDI-1, a novel selective HDAC2 inhibitor, in AS. Fluorescence affinity assays and molecular docking were employed to assess HDI-1 binding to HDAC2. Histone acetylation, lipid accumulation, and expression of lipid transporters (ABCA1, CD36) were evaluated in PMA-differentiated THP-1 macrophages using Western blot, Oil Red O staining, and immunofluorescence. Reactive oxygen species (ROS) levels and Nrf2/HO-1 pathway activation were also measured. In vivo, the efficacy of HDI-1 was examined in high-fat diet-fed ApoE
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied Atherosclerosis. HDI-1 was evaluated. A novel selective histone deacetylase 2 inhibitor (HDI-1) suppresses lipid accumulation and ameliorates atherosclerosis in apolipoprotein E-deficient mice.
Synapse has enriched 10 related papers. Consider them for comparative context: